No cases of incident HIV over more than 1 year of follow-up in OPERA cohort ...

Only one person developed HIV infection in year-long extensions of two PURPOSE trials ...

Gilead Sciences’ HIV prevention business reached a milestone, exceeding $1 billion in quarterly sales for the first time. | ...

Researchers also find low rates of uptake for those with high copays or without commercial insurance, suggesting cost ...

The US Preventive Services Task Force (USPSTF) announced its recommendation for HIV pre-exposure prophylaxis (PrEP). The US Preventive Services Task Force (USPSTF) granted an “A” grade for HIV ...

HIV (human immunodeficiency virus) remains a significant global health challenge, affecting millions of people worldwide. While advancements in medical science have led to better management of the ...

Several interconnecting barriers continue to hinder PrEP access and exacerbate HIV prevention disparities.

Gilead raises its 2026 base-business outlook as HIV and PrEP momentum strengthens, while Trodelvy growth and two potential ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A new pre-exposure prophylaxis (PrEP) drug has shown promise as a ...

About 60% of older Americans take a cholesterol-lowering statin to prevent heart attack, stroke, and other forms of cardiovascular disease. In contrast, only 25% of eligible, HIV-negative people take ...

Up until 2012, there was only one way to protect yourself from acquiring the Human Immunodeficiency Virus (HIV) from sex: wearing condoms. While condoms are still a great preventive tool, there’s ...